• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$88.59 -$0.06 (-0.07%)

REAL-TIME: Last trade at

Shire plc (ADR)

NASDAQ:SHPGY

Shire Presents Data on Venvanse - Analyst Blog

Watson and Shire in Legal Battle - Analyst Blog

Why Shire May Be About to Take Off

Pfizer, Gilead Sciences, Arena Pharmaceuticals Face Big Dates in May [UPDATE]

Are Supply Troubles a Biotech Buying Opportunity?

This Biotech Needs to Strike Fast

CORRECT: FDA Approves Protalix, Pfizer Drug To Treat Gaucher Disease

UPDATE: FDA Approves Protalix, Pfizer Drug To Treat Gaucher Disease

The Big Bet on Protalix

Pharma M&A Surge Spurred By Necessity And Opportunity

Revenues Rise at Shire - Analyst Blog

Shire: Study Shows Vyvanse Has Promise Treating Binge Eating

Shire Expects Good Earnings Momentum As Profit Rises

Shire Beats on Revenue, Matches Expectations on EPS

Drug stocks, miners support FTSE 100, banks slip

Shire to Buy Pervasis Therapeutics - Analyst Blog

Shire Buying Pervasis To Advance Regenerative Medicines Business

Supernus Pharma Unveils Estimated Terms Of IPO

12 Healthcare Dividend Stocks With Gaining Earnings Momentum

Why Shire May Be About to Take Off

Shire: Top-line Results Of The PREVENT2 Trial

Investors Faint From FDA Rejection

Will the FDA Approve Chelsea's Northera?

Replagal BLA Withdrawn by Shire - Analyst Blog

Shire to Buy FerroKin BioSciences - Analyst Blog

UK's Shire To Expand Blood Drug Portfolio With US Biotech Buy

WSJ: Europe's Stocks Finish Higher

ADR Report: Shares Lower As Gold Futures Tumble

Shire's Fosrenol Oral Powder Approved - Analyst Blog

Shire Initiates Trials for Vyvanse - Analyst Blog

SNY Starts Delivering from New Unit - Analyst Blog

Shire and arGEN-X Ink Deal - Analyst Blog

EMA Approves Shire's Vpriv Unit - Analyst Blog

Biotech Investors, Take Note: Margin of Victory Matters

Shire Beats Estimates All the Way - Analyst Blog

Shire 4Q Pretax Profit $296.3M, Sees Good 2012 Earnings Growth

Shire's Profits and Sales Beat Views, Forecasts Strong 2012

Sangamo BioSciences To Partner With Shire To Develop DNA Technology

Reasons To Stay Interested in SNWV - Analyst Blog

Reasons To Stay Interested in SNWV - Analyst Blog

See More Articles...